PTx811

PTx811 is a novel small molecule drug candidate developed for the treatment of multi-drug resistant Staphylococcus aureus (MRSA) skin and soft tissue infections. It is designed for topical administration and has demonstrated efficacy in resolving infections that are refractory to all approved antibiotics, with no reinfection observed after a 14-day daily topical regimen. The compound is part of Primal Therapies' pipeline targeting antimicrobial resistance (AMR), leveraging proprietary combinations to disrupt biofilms and restore microbiome balance. The specific mechanism of action, molecular target(s), or chemical structure have not been publicly disclosed as of June 2025[3].